Who
Karen H. Vousden
Director
Company insider
Files Form 4 as: Director, Faeth Therapeutics; Director, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Jan 2018
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | FTH Faeth Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | FTH Faeth Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.367 at $55.05 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.37 at $55.05 | filing |
| 1 Feb 2025filed 4 Feb 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $210K3,562.34 at $58.95 | filing |
| 1 Feb 2024filed 5 Feb 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $210K4,314.77 at $48.67 | filing |
| 1 Feb 2023filed 3 Feb 2023 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K2,807.81 at $71.23 | filing |
| 1 Feb 2022filed 3 Feb 2022 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K3,067.96 at $65.19 | filing |
| 1 Feb 2021filed 3 Feb 2021 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $190K3,054.17 at $62.21 | filing |
| 31 Dec 2020filed 5 Jan 2021 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $9,687156.17 at $62.03 | filing |
| 30 Sep 2020filed 2 Oct 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $9,687160.68 at $60.29 | filing |
| 30 Jun 2020filed 2 Jul 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $9,687164.75 at $58.80 | filing |
| 31 Mar 2020filed 2 Apr 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $9,688173.8 at $55.74 | filing |
| 1 Feb 2020filed 4 Feb 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $190K3,018.27 at $62.95 | filing |
| 31 Dec 2019filed 3 Jan 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $39K603.68 at $64.19 | filing |
| 30 Sep 2019filed 2 Oct 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $39K764.15 at $50.71 | filing |
| 30 Jun 2019filed 2 Jul 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K769.96 at $45.35 | filing |
| 31 Mar 2019filed 2 Apr 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $31K655 at $47.71 | filing |
| 1 Feb 2019filed 5 Feb 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $185K3,708.16 at $49.89 | filing |
| 31 Dec 2018filed 3 Jan 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $7,813150.3 at $51.98 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.